[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482704":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":19,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hydromorphone","EXPERIMENTAL","Hydromorphone was administered intravenously at a rate of 0.03 mg\u002Fkg\u002Fh for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the content of hydromorphone and hydromorphone-3-glucuronide (the main metabolite) was detected by quantitative liquid chromatography tandem mass spectrometry. And then a population pharmacokinetic model of hydromorphone in patients under ECMO was established.",[13],"Drug: Hydromorphone",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Hydromorphone was administered intravenously at a rate of 0.03 mg\u002Fkg\u002Fh for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"You Shang, Prof.","CONTACT","008602785351607","you_shanghust@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Wuhan Union Hospital","RECRUITING","Wuhan","Hubei","430022","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.26667,30.58333,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":19,"email":25},"You Shang","15972127819",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Xiaobo Yang, MD","Clinical Professor","100482704","phase-2-the-effects-of-ecmo-on-the-pharmacokinetics-of-hydromorphone-100482704",false,"NCT05565495","The Effects of ECMO on the Pharmacokinetics of Hydromorphone","Inclusion Criteria:\n\n* Between the ages of 18 and 80;\n* Using hydromorphone for pain relief;\n* Using ECMO for more than 96h\n\nExclusion Criteria:\n\n* Allergic to hydromorphone;\n* Use of CRRT during ECMO;\n* Liver function Child-Pugh B, C grade;\n* Pregnancy;\n* Intestinal obstruction;\n* Refused to sign the informed consent.","ALL","18 Years","80 Years",{"count":59,"type":60},26,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.",[66],"Extracorporeal Membrane Oxygenation",[66,68,9],"Pharmacokinetics","2024-08-05",{"date":71,"type":72},"2024-08-06","ACTUAL",{"date":74,"type":72},"2022-01-01",{"date":76,"type":60},"2024-09-01",{"name":47,"class":6},1]